Clinical Trials
 Based
upon ReceptoPharm's positive in-vitro and in-vivo
data, it is planned to move into full regulatory
trials as quickly as possible. ReceptoPharm has
identified potential clinical trial sites suitable
to its needs and is in discussions with potential
principal investigators.
In May, ReceptoPharm received approval from the
Medicines Health and Regulatory Agency (MHRA)
for its application of human clinical trials for
the treatment of Adrenomyeloneuropathy (AMN).
The MHRA is the medical regulatory agency within
the British Department of Health.
ReceptoPharm is confident that the available
data from prior IND studies, in addition to the
preliminary clinical data from HIV patients, will
expedite its entry into controlled studies in
the antiviral sector.
|
